Brookline Capital Markets Predicts FBRX FY2026 Earnings

Forte Biosciences, Inc. (NASDAQ:FBRX) – Brookline Capital Markets lowered their FY2026 EPS estimates for Forte Biosciences in a report issued on Monday, April 6th. Brookline Capital Markets analyst K. Raja now expects that the company will post earnings per share of ($4.44) for the year, down from their prior estimate of ($2.72). The consensus estimate for Forte Biosciences’ current full-year earnings is ($12.12) per share. Brookline Capital Markets also issued estimates for Forte Biosciences’ FY2027 earnings at ($3.26) EPS, FY2028 earnings at ($2.92) EPS and FY2029 earnings at ($7.49) EPS.

Forte Biosciences (NASDAQ:FBRX) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($1.45) EPS for the quarter, missing analysts’ consensus estimates of ($1.42) by ($0.03).

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Forte Biosciences in a research note on Friday, March 27th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Forte Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $67.00.

Forte Biosciences Stock Performance

NASDAQ:FBRX opened at $26.27 on Thursday. Forte Biosciences has a 52 week low of $4.90 and a 52 week high of $35.62. The firm has a market cap of $364.89 million, a price-to-earnings ratio of -5.51 and a beta of 3.20. The firm’s 50-day simple moving average is $28.33 and its 200 day simple moving average is $22.91.

Institutional Investors Weigh In On Forte Biosciences

A number of large investors have recently bought and sold shares of FBRX. Federated Hermes Inc. acquired a new stake in Forte Biosciences during the second quarter worth about $13,864,000. Orbimed Advisors LLC grew its stake in Forte Biosciences by 101.8% during the second quarter. Orbimed Advisors LLC now owns 1,196,955 shares of the company’s stock worth $15,477,000 after buying an additional 603,867 shares in the last quarter. Adage Capital Partners GP L.L.C. acquired a new stake in Forte Biosciences during the second quarter worth about $4,310,000. Cable Car Capital LP grew its stake in Forte Biosciences by 127.7% during the second quarter. Cable Car Capital LP now owns 500,000 shares of the company’s stock worth $6,465,000 after buying an additional 280,396 shares in the last quarter. Finally, Jain Global LLC acquired a new stake in Forte Biosciences during the fourth quarter worth about $5,520,000. 77.63% of the stock is currently owned by institutional investors and hedge funds.

More Forte Biosciences News

Here are the key news stories impacting Forte Biosciences this week:

• Neutral Sentiment: Press coverage and analyst roundups that review Forte’s outlook and clinical program; background context for investors. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: Forte priced a sizeable underwritten public offering of 5,709,936 shares at $26.27 per share (company granted underwriters a 30‑day option for up to 856,490 additional shares). All shares are being sold by Forte — the deal will be dilutive and likely puts near‑term downward pressure on the share price, though it does raise cash to fund operations. Forte Biosciences Announces Pricing of $150 Million Public Offering TipRanks: Forte Biosciences Prices $150 Million Public Offering
• Negative Sentiment: Brookline Capital Markets sharply reduced multi‑year EPS forecasts for Forte (FY2026–FY2030), cutting earlier projections across several years — the revisions signal the analyst expects larger near‑term losses than previously modeled and remove upside from earnings/cash‑flow expectations. That weaker analyst outlook amplifies negative sentiment from the equity offering. (See FBRX analyst notes on MarketBeat.) MarketBeat: FBRX Analyst Coverage

About Forte Biosciences

Forte Biosciences, Inc is a clinical-stage biotechnology company focused on developing innovative treatments to restore skin health by targeting the underlying biology of the skin barrier and microbiome. Headquartered in San Diego, California, Forte leverages proprietary platforms to discover and advance topical live biotherapeutic products and skin barrier therapies aimed at addressing serious dermatological conditions.

The company’s lead product candidate, FB-401, is a topical live biotherapeutic formulation designed to rebalance the skin microbiome in patients with atopic dermatitis.